Abstract:Background Dilated cardiomyopathy (DCM), characterized by progressive left ventricular enlargement and systolic dysfunction, is the most common type of cardiomyopathy and a leading cause of heart failure and cardiac death. Accumulating evidence underscores the critical role of genetic defects in the pathogenesis of DCM, and >250 genes have been implicated in DCM to date. However, DCM is of substantial genetic heterogeneity, and the genetic basis underpinning DCM remains elusive in most cases. Methods and Results By genome‐wide scan with microsatellite markers and genetic linkage analysis in a 4‐generation family inflicted with autosomal‐dominant DCM, a new locus for DCM was mapped on chromosome 15q13.1–q13.3, a 4.77‐cM (≈3.43 Mbp) interval between markers D15S1019 and D15S1010, with the largest 2‐point logarithm of odds score of 5.1175 for the marker D15S165 at recombination fraction (θ)=0.00. Whole‐exome sequencing analyses revealed that within the mapping chromosomal region, only the mutation in the KLF13 gene, c.430G>T (p.E144X), cosegregated with DCM in the family. In addition, sequencing analyses of KLF13 in another cohort of 266 unrelated patients with DCM and their available family members unveiled 2 new mutations, c.580G>T (p.E194X) and c.595T>C (p.C199R), which cosegregated with DCM in 2 families, respectively. The 3 mutations were absent from 418 healthy subjects. Functional assays demonstrated that the 3 mutants had no transactivation on the target genes ACTC1 and MYH7 (2 genes causally linked to DCM), alone or together with GATA4 (another gene contributing to DCM), and a diminished ability to bind the promoters of ACTC1 and MYH7 . Add, the E144X‐mutant KLF13 showed a defect in intracellular distribution. Conclusions This investigation indicates KLF13 as a new gene predisposing to DCM, which adds novel insight to the molecular pathogenesis underlying DCM, implying potential implications for prenatal prevention and precision treatment of DCM in a subset of patients. Nonstandard Abbreviations and Acronyms DCM dilated cardiomyopathy WES whole‐exome sequencing Clinical Perspective What Is New? By genome‐wide screening with microsatellite markers and genetic linkage analysis in a 4‐generation family suffering from autosomal‐dominant dilated cardiomyopathy (DCM), a new locus for DCM was mapped on chromosome 15q13.1–q13.3. A novel mutation in the KLF13 gene, c.430G>T (p.E144X), was identified by whole‐exome sequencing analysis to cosegregate with DCM in the family within the mapping chromosomal region; sequencing analyses of KLF13 in another cohort of 266 unrelated patients with DCM and their available family members revealed 2 novel mutations, c.580G>T (p.E194X) and c.595T>C (p.C199R), which cosegregated with DCM in 2 families, respectively. The 3 mutants had no transactivation on the target genes ACTC1 and MYH7 , alone or together with GATA4, and the 3 mutations showed a diminished ability to bind the promoters of ACTC1 and MYH7 ; the E144X‐mutant KLF13 showed a defect in intracellular distribution. What Are the Clinical Implications? The discovery of a new DCM‐causative gene has potential implications for antenatal prophylaxis and precise management of DCM. The DCM‐associated genetic data may be used for prognostic risk stratification of patients with DCM. Dilated cardiomyopathy (DCM), defined by left ventricular enlargement with systolic dysfunction at the exclusion of other usual clinically detectable causes responsible for impaired global contractile function, is the most prevalent form of myocardial disease in humans, with an estimated prevalence of up to 1 in 250 individuals worldwide. 1 , 2 , 3 Notably, there is a significant sex difference in the incidence of DCM, with an overall combined mean male:female sex ratio of 2.5:1. 4 DCM confers a significantly enhanced risk for heart failure, ventricular and supraventricular dysrhythmias, cardiac transplantation, and death. 5 , 6 , 7 , 8 , 9 F -Abstract Truncated-

VEZF1 Loss-of-function Mutation Underlying Familial Dilated Cardiomyopathy.

ZBTB17 Loss-of-function Mutation Contributes to Familial Dilated Cardiomyopathy

CASZ1 Loss-of-function Mutation Contributes to Familial Dilated Cardiomyopathy

Association Between SCN5A R225Q Variant and Dilated Cardiomyopathy: Potential Role of Intracellular Ph and WNT/β-catenin Pathway

Identification and Functional Characterization of KLF5 As a Novel Disease Gene Responsible for Familial Dilated Cardiomyopathy.

Detection and functional characterization of a novel <i>MEF2A</i> variation responsible for familial dilated cardiomyopathy

MEF2C loss-of-function mutation associated with familial dilated cardiomyopathy.

TBX20 Loss-of-function Mutation Associated with Familial Dilated Cardiomyopathy.

Identification of a LMNA (c.646c > T) Variant by Whole-Exome Sequencing in Combination with a Dilated Cardiomyopathy (DCM) Related Gene Filter in a Family with Familiar DCM

A Novel GATA4 Loss-of-function Mutation Responsible for Familial Dilated Cardiomyopathy

Gata6 Loss-Of-Function Mutations Contribute To Familial Dilated Cardiomyopathy

TBX5 Loss-of-function Mutation Contributes to Familial Dilated Cardiomyopathy

Identification of gene mutation associated with familial dilated cardiomyopathy by whole-exome sequencing

Genetic Determinant of Familial Dilated Cardiomyopathy and Genotype-Targeted Therapeutic Strategy

A Novel Nkx2-5 Loss-Of-Function Mutation Predisposes to Familial Dilated Cardiomyopathy and Arrhythmias

Genetic Mutation of Familial Dilated Cardiomyopathy Based on Next‑generation Semiconductor Sequencing.

GATA5 Loss-of-function Mutation in Familial Dilated Cardiomyopathy.

KLF13 Loss‐of‐Function Mutations Underlying Familial Dilated Cardiomyopathy

HAND1 loss-of-function mutation associated with familial dilated cardiomyopathy.

Study of Pathogenic Genes in a Pedigree with Familial Dilated Cardiomyopathy

GATA4 Loss-of-function Mutation Underlies Familial Dilated Cardiomyopathy.